ReviewBritish journal of pharmacology2008
The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?
Review in British journal of pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 176 citations in OpenAlex.
- Inflammatory Biomarkers Predict Domain-Specific Cognitive Decline in Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2017Trial
- Macitentan: entry-into-humans study with a new endothelin receptor antagonist.European journal of clinical pharmacology · 2011Trial
- Selective endothelin-1 receptor type A inhibition in subjects undergoing cardiac surgery with preexisting left ventricular dysfunction: Influence on early postoperative hemodynamics.The Journal of thoracic and cardiovascular surgery · 2010Trial
- Article
- Dexamethasone-Induced Arterial Stiffening Is Attenuated by Training due to a Better Balance Between Aortic Collagen and Elastin Levels.Cardiovascular drugs and therapy · 2024Article
- Advances in biomarkers for vasospasm - Towards a future blood-based diagnostic test.World neurosurgery: X · 2024Review
- Endothelial cell dysfunction in cardiac disease: driver or consequence?Frontiers in cell and developmental biology · 2023Review
- A bioassay system of autologous human endothelial, smooth muscle cells, and leukocytes for use in drug discovery, phenotyping, and tissue engineering.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- G protein-coupled receptor 37L1 regulates renal sodium transport and blood pressure.American journal of physiology. Renal physiology · 2019Article
- A historical perspective on the role of sensory nerves in neurogenic inflammation.Seminars in immunopathology · 2018Review
- Fibroblast growth factor 21 attenuates inflammation and oxidative stress in atherosclerotic rat via enhancing the Nrf1-ARE signaling pathway.International journal of clinical and experimental pathology · 2018Article
- Endothelin-1 promotes hypertrophic remodelling of cardiac myocytes by activating sustained signalling and transcription downstream of endothelin type A receptors.Cellular signalling · 2017Article
- Smooth Muscle Endothelin B Receptors Regulate Blood Pressure but Not Vascular Function or Neointimal Remodeling.Hypertension (Dallas, Tex. : 1979) · 2017Article
- News from Tartary: an ethnopharmacological approach to drug and therapeutic discovery.British journal of clinical pharmacology · 2017Review
- Immature endothelial cells initiate endothelin-mediated constriction of newborn arteries.The Journal of physiology · 2016Article
- Endothelin-1 shifts the mediator of bradykinin-induced relaxation from NO to H2 O2 in resistance arteries from patients with cardiovascular disease.British journal of pharmacology · 2016Article
- New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon?Current hypertension reports · 2015Review
- Selective endothelin A receptor antagonism with sitaxentan reduces neointimal lesion size in a mouse model of intraluminal injury.British journal of pharmacology · 2015Article
- Pulmonary artery smooth muscle cell endothelin-1 expression modulates the pulmonary vascular response to chronic hypoxia.American journal of physiology. Lung cellular and molecular physiology · 2015Article
- Adaptations of the endothelin system after exercise training in a porcine model of ischemic heart disease.Microcirculation (New York, N.Y. : 1994) · 2015Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is considerable evidence that the potent vasoconstrictor endothelin-1 (ET-1) contributes to the pathogenesis of a variety of cardiovascular diseases. As such, pharmacological manipulation of the ET system might represent a promising therapeutic goal. Many clinical trials have assessed the potential of ET receptor antagonists in cardiovascular disease, the most positive of which have resulted in the licensing of the mixed ET receptor antagonist bosentan, and the selective ET(A) receptor antagonists, sitaxsentan and ambrisentan, for the treatment of pulmonary arterial hypertension (PAH). In contrast, despite encouraging data from in vitro and animal studies, outcomes in human heart failure have been disappointing, perhaps illustrating the risk of extrapolating preclinical work to man. Many further potential applications of these compounds, including resistant hypertension, chronic kidney disease, connective tissue disease and sub-arachnoid haemorrhage are currently being investigated in the clinic. Furthermore, experience from previous studies should enable improved trial design and scope remains for development of improved compounds and alternative therapeutic strategies. Although ET-converting enzyme inhibitors may represent one such alternative, there have been relatively few suitable compounds developed, and consequently, clinical experience with these agents remains extremely limited. Recent advances, together with an increased understanding of the biology of the ET system provided by improved experimental tools (including cell-specific transgenic deletion of ET receptors), should allow further targeting of clinical trials to diseases in which ET is involved and allow the therapeutic potential for targeting the ET system in cardiovascular disease to be fully realized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.